Ferric carboxymaltose in patients with heart failure and iron deficiency.

By S. Anker, J. Comin Colet, Gerasimos Filippatos, R. Willenheimer, K. Dickstein, H. Drexler, T. Lüscher, B. Bart, W. Banasiak, J. Niegowska and 6 more. New England Journal of Medicine, 2009

1,858 citations recorded by the source corpus.

Subfields: Genetics, Hematology

View Paper: https://www.semanticscholar.org/paper/71cdee0767b1d0fa4ec6d8ca0606b7e252ce0c2f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Kai-Uwe Eckardt
2. Donat R. Spahn
3. B. Kasiske

In Hematology

1. Donat R. Spahn

Citations in the corpus

• Narrative Review (2012, background): “5 g/dL).(105) Intravenous iron should therefore be considered in patients (nonseptic) with ADHF who have an iron-deficiency anemia.”
• 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016, neutral): “15 g/dL.(469,470) Patients with iron deficiency need to be screened”
• Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). (2011, background): “105,106 Erythropoiesis-stimulating agents and/ or intravenous iron 107 may improve exercise tolerance but are without survival benefit.”